VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | Nivolumab, ipilimumab and panitumumab in mCRC

VJOncology is committed to improving our service to you

Stacey Cohen

Stacey Cohen, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the rationale and study design of a Phase II clinical trial investigating the clinical efficacy of nivolumab, ipilimumab, and panitumumab in patients with unresectable refractory KRAS/NRAS/BRAF wild-type microsatellite stable metastatic colorectal cancer (mCRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter